Australia's aging population and rising rates of orthopedic conditions have driven a surge in demand for joint replacements, with over 85,000 hip and knee procedures performed annually. However, traditional implants made from materials like titanium or stainless steel often lead to complications such as infections, stress shielding due to stiffness mismatch with bone, and the need for revision surgeries. At Flinders University, researchers are tackling these challenges head-on with innovative alloy developments that promise safer, more effective medical devices.

Biomedical engineers at Flinders, located in Adelaide, South Australia, are pioneering materials that not only mimic the mechanical properties of human bone but also degrade naturally over time. This eliminates the need for secondary surgeries to remove implants, reducing patient risk and healthcare costs while promoting faster healing.

Flinders' Groundbreaking Magnesium-Based Alloys

The latest advancement from Flinders University's College of Science and Engineering involves a new family of biodegradable magnesium alloys formulated as Mg-xZn-yZr-1Y, where yttrium remains fixed at 1 weight percent, while zinc (Zn) and zirconium (Zr) vary. These alloys are designed specifically for orthopedic applications like screws, plates, and pins used in fracture fixation.

Led by Senior Lecturer Dr. Reza Hashemi, the team systematically tested six compositions, varying Zn from 1 to 5 wt% and Zr from 0.25 to 1 wt%. The standout performer, Mg-3Zn-0.5Zr-1Y, demonstrated exceptional balance: a tensile strength of 201.6 MPa, yield strength of 80.7 MPa, Young's modulus of 40.4 GPa—closely matching cortical bone's range of 17-20 GPa—and 11.8% elongation before fracture. These properties address the stress shielding issue common with stiffer metals like Ti-6Al-4V (110 GPa), which can weaken surrounding bone over time.

Mastering Corrosion for Controlled Degradation

One of the biggest hurdles for magnesium alloys in implants is rapid corrosion, which can cause premature failure or excessive hydrogen gas buildup, leading to inflammation. Flinders researchers refined the microstructure through precise alloying, achieving a corrosion current density of just 1.77 µA/cm² and a hydrogen evolution rate (HER) of 0.017 ml/cm²/hr for the optimal alloy—far superior to benchmarks like AZ91.

Potentiodynamic polarization tests in phosphate-buffered saline (PBS, pH 7.4) revealed an open circuit potential (OCP) of -1.521 V, indicating stability. Higher Zr content (0.5-1 wt%) refined grains to around 101 µm, forming protective intermetallic phases that slow degradation to match healing timelines, typically 6-12 months for bone fractures.

"These new alloys not only improve mechanical performance but also enhance corrosion resistance, critical for implants designed to safely degrade inside the body," explains Dr. Hashemi. This controlled breakdown ensures structural integrity during healing while fully dissolving afterward.

From Lab to Alloy Optimization: The Research Process

The alloys were cast at Beihang University in China using pure magnesium, zinc, and master alloys under protective atmosphere to prevent oxidation. Samples underwent homogenization, polishing, and rigorous characterization using optical microscopy, scanning electron microscopy (SEM), energy-dispersive spectroscopy (EDS), tensile testing per ASTM E8M, Vickers hardness, and electrochemical corrosion analysis.

Master's graduate Win Ken Look's thesis work was pivotal, identifying how Zn boosts strength via solid solution hardening but excess (>3 wt%) forms brittle phases reducing ductility. Zr acts as a grain refiner, with 0.5 wt% optimal before embrittlement at 1 wt%. Yttrium stabilizes the microstructure, enhancing overall biocompatibility.

Facilities like Flinders Microscopy and Microanalysis, supported by Microscopy Australia and the Australian National Fabrication Facility, enabled high-resolution imaging of corrosion products post-immersion, confirming uniform degradation layers on the top alloy.

Building on Flinders' Legacy of Implant Innovation

This magnesium alloy work builds on prior Flinders successes. In 2024, Rhianna McHendrie's master's research yielded Ti-33Nb-xGa (x=3,5 wt%) alloys with Young's modulus reduced to 67-75 GPa (37-44% lower than Ti-6Al-4V) and 90-95% kill rates against Staphylococcus aureus and Pseudomonas aeruginosa—key implant pathogens.Published in Journal of Functional Biomaterials.

More recently, in 2025, the Biomedical Nanoengineering Laboratory integrated silver-gallium liquid metal nanoparticles into 3D-printed bioceramic scaffolds, boosting osteogenesis and combating infections. Professor Krasimir Vasilev's team confirmed dual benefits: antimicrobial action and bone growth promotion.

These efforts position Flinders as a hub for advanced biomaterials, addressing Australia's high orthopedic implant failure rates—around 1.7% infections post-joint replacement, with 6% escalating to intensive care.

The Team Behind the Breakthrough

Dr. Reza Hashemi, with expertise in biomaterials mechanics and fretting wear, leads the charge. His research spans computational modeling and experimental validation for implant durability. Collaborators include Lisseth KR Antolinez and Mohsen Feyzi at Flinders, and Associate Professor Wenlong Xiao at Beihang, funded by Beijing's Natural Science Foundation.

Win K. Look's graduate work exemplifies Flinders' hands-on training, producing publishable results early in careers. The Medical Device Research Institute (MDRI) fosters this interdisciplinary environment, blending engineering, medicine, and nanotechnology.

Australian Context: Rising Demand and Innovation Needs

With joint replacements up due to obesity, sports injuries, and demographics, Australia faces mounting pressure on its healthcare system. Traditional implants' limitations—infection (5-10% globally), loosening (10-20% after 10 years), and revisions (costing $20,000+ each)—underscore the need for alternatives.

Flinders' alloys could cut revision rates, saving millions. Biodegradables align with Australia's medtech sector, valued at $4.8 billion, employing 42,000. Universities like Flinders drive 70% of med device R&D, partnering with industry via MDRI.

Stakeholders, including the Australian Orthopaedic Association, praise such university-led advances for enhancing patient mobility and quality of life.

Towards Clinical Translation and Future Prospects

Preclinical promise paves the way for in vivo animal trials, then human studies. Similar Mg alloys like WE43 are in global trials (e.g., Germany, China), showing 12-18 month degradation with bone union rates >95%.

Flinders eyes ISO 10993 biocompatibility certification and 3D printing integration for patient-specific implants. Challenges remain: fine-tuning degradation for diverse anatomies and scaling production.

"Refining microstructure controls breakdown, reducing premature failure risks," notes Hashemi. International collaborations, like with Beihang, accelerate progress toward commercialization.

Flinders University's Leadership in Biomedical Engineering

Flinders stands out among Australian universities for medtech innovation. The Tonsley campus integrates MDRI with industry, hosting advanced facilities like electron beam melting for custom implants. Programs in biomedical engineering attract top talent, with graduates entering roles at Cochlear, ResMed, and startups.

This research highlights higher education's role in translating discoveries to real-world impact, supported by ARC grants and NCRIS infrastructure.

Photo by Kanchanara on Unsplash

Career Pathways in Australia's Medtech Sector

• Research Roles: PhD opportunities in biomaterials at Flinders, focusing on alloys and nanotech.
• Industry Positions: Design engineers for implant firms, leveraging uni research.
• Clinical Translation: Regulatory specialists ensuring TGA approval.
• Academic Tracks: Lecturers training next-gen engineers.

Australia's medtech growth offers adjunct professor jobs, postdocs, and faculty positions in higher ed, particularly in South Australia.